重组人血管内皮抑素静脉泵入联合化疗治疗晚期结肠癌的疗效观察

Clinical observation of recombinant human endostatin durative transfusion combined with chemotherapy in advanced colon cancer

目的探讨重组人血管内皮抑素静脉泵入联合化疗在晚期结肠癌治疗中的疗效及安全性。方法 36例晚期结肠癌患者采用重组人血管内皮抑素持续静脉泵入联合化疗。重组人血管内皮抑素注射液15mg/(m2·d),连续14d;在第4d开始化疗,化疗方案选用XELOX、m FOLFOX6、FOLFIRI。结果 36例患者均完成至少2个周期的治疗,完全缓解1例,部分缓解15例,稳定14例,进展6例,有效率(RR)为44.4%。治疗过程中与重组人血管内皮抑素相关的主要不良反应为1例2级窦性心动过速;化疗不良反应主要为主要表现为中性粒细胞减少、恶心、呕吐、腹泻等,程度较轻,无化疗相关死亡。结论重组人血管内皮抑素静脉泵入联合化疗治疗晚期结肠癌的近期疗效较好,不良反应可耐受。

Objective To investigate the safety and efficacy recombinant human endostatin durative transfusion combined with chemotherapy in colon cancer Methods Totally 36 patients with advanced colon cancer were treated with recombinant human endostatin durative transfusion combined with chemotherapy. Recombinant human endostatin（ 15 mg / m^2） was durative transfused every 24 hours for 14 days,and in the fourth day,patientswere received XELOX / m FOLFOX6 / FOLFIRI chemotherapy. Results Every patient was received at least 2 cycles,got 1 case of CR,15 cases of PR,14 cases of SD and 6 cases of PD. The objective response rate（ RR） was 44. 4%,Major toxicities related with recombinant human endostatin were sinus tachycardia in 1 case. The main side effects of chemotherapy were neutropenia,nausea,vomiting,diarrhea,and no chemotherapy related death. Conclusion Recombinant human endostatin durative transfusion combined with chemotherapy for advanced colon cancer was safety and efficacy.